Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This research study is examining whether Neratinib has any activity in participants with
prostate cancer that has spread and is no longer responding to hormonal treatment.
- The names of the study drug involved in this study is neratinib.